Skip to main content

Advertisement

SpringerLink
Log in

Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL)

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Chronic lymphocytic leukemia (CLL) can trigger autoimmune phenomena, with immune thrombocytopenia (ITP) the most common presentation. Upon cessation of CLL therapy, including ibrutinib, autoimmune flares can occur. In a 68-year-old man with CLL, ibrutinib was held for 2 weeks prior to elective shoulder surgery. Eleven days after stopping therapy, he presented with a purpuric rash on his right hip, buttock, and lower extremities. He experienced two episodes of seizure activity while hospitalized. MRI brain demonstrated patchy areas of altered signal involving deep white matter and sub-cortical white matter structures concerning for cerebral vasculitis. Although there was no evidence of hemolysis, serum cold agglutinin titer was elevated at > 1:512 and cryoglobulin levels were positive at 36%. He was diagnosed with type I cryoglobulinemia and treated with rituximab, plasmapheresis, methylprednisolone, and ibrutinib was restarted. This regimen resolved his symptoms. A rare complication of CLL is the production of cryoglobulins, which can present at initial diagnosis or in relapsed disease. Our case demonstrates that the cessation of ibrutinib therapy, even for a short time, can precipitate complications. To our knowledge, we report the first case of a patient with well-controlled CLL who rapidly developed cryoglobulinemic vasculitis after stopping ibrutinib therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegal R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

    Article  Google Scholar 

  2. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010;23(1):47–59.

    Article  CAS  Google Scholar 

  3. Ruzickova S, Pruss A, Odendahl M, Wolbart K, Burmester GR, Scholze J, et al. Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in V(H)4-34 expressing single leukemic B cells. Blood. 2002;100(9):3419–22.

    Article  CAS  Google Scholar 

  4. Berentsen S, Bø K, Shammas FV, Myking AO, Ulvestad E. Chronic cold agglutinin disease of the “idiopathic” type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS. 1997;105(5):354–62.

    Article  CAS  Google Scholar 

  5. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.

    Article  CAS  Google Scholar 

  6. Lewis FB, Schwartz RS, Dameshek W. X-radiation and alkylating agents as possible “trigger” mechanisms in the autoimmune complications of malignant lymphophroliferative disease. Clin Exp Immunol. 1966;1(1):3–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Barcellini W, Capalbo S, Agostinelli RM, Mauro FR, Ambrosetti A, Calori R, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica. 2006;91(12):1689–92.

    PubMed  Google Scholar 

  8. Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016;30(2):346–50.

    Article  CAS  Google Scholar 

  9. Sato R, Jacob J, Gaballa S. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2017;59(7):1–4.

    Google Scholar 

  10. Brouet J-C, Clauvel J-P, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med. 1974;57(5):775–88.

    Article  CAS  Google Scholar 

  11. Meltzer M, Franklin EC. Cryoglobulinemia—a study of twenty-nine patients. Am J Med. 1966;40(6):828–36.

    Article  CAS  Google Scholar 

  12. Morra E. Cryoglobulinemia. Hematol Am Soc Hematol Educ Progr 2005;1(1):368–72.

    Article  Google Scholar 

  13. Xu W, Wang Y-H, Fan L, Fang C, Zhu DX, Wang DM, et al. Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia. Leuk Res. 2011;35(8):1060–5.

    Article  CAS  Google Scholar 

  14. Michael AB, Lawes M, Kamalarajan M, Huissoon A, Pratt G. Cryoglobulinaemia as an acute presentation of waldenstrom’s macroglobulinaemia. Br J Haematol. 2004;124(5):565.

    Article  Google Scholar 

  15. Payet J, Livartowski J, Kavian N, Chandesris O, Dupin N, Wallet N, et al. Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leuk Lymphoma. 2013;54(4):767–77.

    Article  CAS  Google Scholar 

  16. Néel A, Perrin F, Decaux O, Dejoie T, Tessoulin B, Halliez M, et al. Long-term outcome of monoclonal (type 1) cryoglobulinemia. Am J Hematol. 2014;89(2):156–61.

    Article  Google Scholar 

  17. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775–88.

    Article  CAS  Google Scholar 

  18. Terrier B, Karras A, Kahn J-E, Guenno GL, Marie I, Benarous L, et al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore). 2013;92(2):61–8.

    Article  CAS  Google Scholar 

  19. Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol. 2013;25(1):10–8.

    Article  Google Scholar 

  20. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology. 2008;2008(1):450–6.

    Article  Google Scholar 

  21. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.

    Article  CAS  Google Scholar 

  22. O’Brien S, Jones JA, Coutre SE, Mato AR, Hillman P, Tam C, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409–18.

    Article  Google Scholar 

  23. Montillo M, O’Brien S, Tedeschi A, Byrd JC, Dearden C, Gill D, et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood Cancer J. 2017;7(2):e524.

    Article  CAS  Google Scholar 

  24. Manda S, Dunbar N, Marx-Wood CR, Danilov AV. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. Br J Haematol. 2015;170(5):734–6.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology/Oncology Department, Medical College of Wisconsin Affiliated Hospitals, 9200 West Wisconsin Ave, Milwaukee, WI, 53226, USA

    Nicholas Wright, Ensi Voshtina, Gemlyn George, Arun Singavi & Joshua Field

  2. 2139A N 72nd St, Wauwatosa, WI, 53213, USA

    Nicholas Wright

Authors
  1. Nicholas Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ensi Voshtina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gemlyn George
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arun Singavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joshua Field
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas Wright.

Ethics declarations

Conflict of interests

The authors have no conflicts of interest to report.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wright, N., Voshtina, E., George, G. et al. Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL). Int J Hematol 110, 751–755 (2019). https://doi.org/10.1007/s12185-019-02729-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-019-02729-4

Keywords

Search

Navigation